Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the …
…, AFH Stalenhoef, E Stroes, MR Taskinen… - European heart …, 2014 - academic.oup.com
Aims Homozygous familial hypercholesterolaemia (HoFH) is a rare life-threatening condition
characterized by markedly elevated circulating levels of low-density lipoprotein cholesterol (…
characterized by markedly elevated circulating levels of low-density lipoprotein cholesterol (…
Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment
…, ES Stroes, MR Taskinen… - European heart …, 2015 - academic.oup.com
Familial hypercholesterolaemia (FH) is a common genetic cause of premature coronary heart
disease (CHD). Globally, one baby is born with FH every minute. If diagnosed and treated …
disease (CHD). Globally, one baby is born with FH every minute. If diagnosed and treated …
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and …
…, G De Backer, I Graham, MR Taskinen… - European heart …, 2011 - academic.oup.com
Surveys and registries are needed to verify that real-life daily practice is in keeping with
what is recommended in the guidelines, thus completing the loop between clinical research, …
what is recommended in the guidelines, thus completing the loop between clinical research, …
Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the …
…, C Pardy, M d'Emden, D Tse, MR Taskinen… - Diabetes …, 2009 - Am Diabetes Assoc
OBJECTIVE—We explored whether cardiovascular disease (CVD) risk and the effects of
fenofibrate differed in subjects with and without metabolic syndrome and according to various …
fenofibrate differed in subjects with and without metabolic syndrome and according to various …
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of …
…, DJ Richter, MS Sabatine, MR Taskinen… - European heart …, 2020 - academic.oup.com
version of the Guidelines, which is freely available via the ESC and EAS websites and
hosted on their journals’ websites (EHJ and Atherosclerosis Journal). The National Cardiac …
hosted on their journals’ websites (EHJ and Atherosclerosis Journal). The National Cardiac …
Cardiovascular morbidity and mortality associated with the metabolic syndrome
…, B Forsen, K Lahti, M Nissen, MR Taskinen… - Diabetes …, 2001 - Am Diabetes Assoc
OBJECTIVE—To estimate the prevalence of and the cardiovascular risk associated with the
metabolic syndrome using the new definition proposed by the World Health Organization (…
metabolic syndrome using the new definition proposed by the World Health Organization (…
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
…, P Barter, J Best, R Scott, MR Taskinen… - Lancet (London …, 2005 - europepmc.org
Background Patients with type 2 diabetes mellitus are at increased risk of cardiovascular
disease, partly owing to dyslipidaemia, which can be amenable to fibrate therapy. We designed …
disease, partly owing to dyslipidaemia, which can be amenable to fibrate therapy. We designed …
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the …
…, B Van De Sluis, MR Taskinen… - European heart …, 2017 - academic.oup.com
Aims To appraise the clinical and genetic evidence that low-density lipoproteins (LDLs)
cause atherosclerotic cardiovascular disease (ASCVD). Methods and results We assessed …
cause atherosclerotic cardiovascular disease (ASCVD). Methods and results We assessed …
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus …
…, AFH Stalenhoef, E Stroes, MR Taskinen… - European heart …, 2013 - academic.oup.com
Aims The first aim was to critically evaluate the extent to which familial hypercholesterolaemia
(FH) is underdiagnosed and undertreated. The second aim was to provide guidance for …
(FH) is underdiagnosed and undertreated. The second aim was to provide guidance for …
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels
…, L Råstam, EK Speliotes, MR Taskinen… - Science, 2007 - science.org
New strategies for prevention and treatment of type 2 diabetes (T2D) require improved insight
into disease etiology. We analyzed 386,731 common single-nucleotide polymorphisms (…
into disease etiology. We analyzed 386,731 common single-nucleotide polymorphisms (…